A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Phase of Trial: Phase III
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Prednisolone; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms PROTEUS
- Sponsors Janssen Research & Development; Janssen-Cilag
- 27 Jun 2019 Status changed from not yet recruiting to recruiting.
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 30 Apr 2019 Planned initiation date changed from 28 Feb 2019 to 11 Jun 2019.